Low-dose aspirin as primary prevention did not appear to significantly reduce the risk of a combined end point of coronary, cerebrovascular and peripheral vascular events in patients with type-2 diabetes, according to a new study. However, aspirin did significantly reduce the combination of fatal coronary and fatal cerebrovascular events.